The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells

Jackson, John K.; Leung, Donna; Burt, Helen

doi:10.1016/j.ultras.2019.106033

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GC Gelatinase-stimuli di-block copolymers poly(ethylene glycol)b-poly(ε-caprolactone) (PEG-b-PCL) copolymers, MePEG114-b-PCL200 and MePEG17b-PCL5 (PCL200/PCL5) + ultrasoundIncreased accumulation of drug[132] …”

mentioning

confidence: 99%

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Milewska¹,

Niemirowicz-Laskowska²,

Siemiaszko³

et al. 2021

IJN

View full text Add to dashboard Cite

Nanotherapy is a part of nanomedicine that involves nanoparticles as carriers to deliver drugs to target locations. This novel targeting approach has been found to resolve various problems, especially those associated with cancer treatment. In nanotherapy, the carrier plays a crucial role in handling many of the existing challenges, including drug protection before early-stage degradations of active substances, allowing them to reach targeted cells and overcome cell resistance mechanisms. The present review comprises the following sections: the first part presents the introduction of pharmacoeconomics as a branch of healthcare economics, the second part covers various beneficial aspects of the use of nanocarriers for in vitro, in vivo, and pre- and clinical studies, as well as discussion on drug resistance problem and present solutions to overcome it. In the third part, progress in drug manufacturing and optimization of the process of nanoparticle synthesis were discussed. Finally, pharmacokinetic and toxicological properties of nanoformulations due to up-to-date studies were summarized. In this review, the most recent developments in the field of nanotechnology’s economic impact, particularly beneficial applications in medicine were presented. Primarily focus on cancer treatment, but also discussion on other fields of application, which are strongly associated with cancer epidemiology and treatment, was made. In addition, the current limitations of nanomedicine and its huge potential to improve and develop the health care system were presented.

show abstract

mentioning

confidence: 99%

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Milewska¹,

Niemirowicz-Laskowska²,

Siemiaszko³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…The published studies have shown that nanoparticles hold promise for a variety of biomedical applications including therapeutic and diagnostic levels [ 31 , 32 ]. Some reports also indicated that they might help to overcome resistance and sensitize cancer cells to classical chemotherapeutic agents [ 33 , 34 ]. Therefore, in the next step, we evaluated the potential of magnetic particles coated by polymeric shells containing poly(cholesteryl acrylate) to sensitize breast cancer cells to doxorubicin.…”

Section: Discussionmentioning

confidence: 99%

Magnetic Particles with Polymeric Shells Bearing Cholesterol Moieties Sensitize Breast Cancer Cells to Low Doses of Doxorubicin

Markiewicz

Niemirowicz-Laskowska

Szymczuk

et al. 2021

IJMS

View full text Add to dashboard Cite

One of the promising strategies for improvement of cancer treatment is application of a combination therapy. The aim of this study was to investigate the anticancer activity of nanoformulations containing doxorubicin and iron oxide particles covered with polymeric shells bearing cholesterol moieties. It was postulated that due to high affinity to cell membranes, particles comprising poly(cholesteryl acrylate) can sensitize cancer cells to doxorubicin chemotherapy. The performed analyses revealed that the developed systems are effective against the human breast cancer cell lines MCF-7 and MDA-MB-231 even at low doses of the active compound applied (0.5 µM). Additionally, high compatibility and lack of toxicity of the tested materials against human red blood cells, immune (monocytic THP-1) cells, and cardiomyocyte H9C2(2-1) cells was demonstrated. Synergistic effects observed upon administration of doxorubicin with polymer–iron oxide hybrids comprising poly(cholesteryl acrylate) may provide an opportunity to limit toxicity of the drug and to improve its therapeutic efficiency at the same time.

show abstract

“…To date, numerous P-gp inhibitors have been developed 24 , 25 , 26 , 27 , such as verapamil (VPM) 28 , 29 , 30 , cyclosporine A 31 , dexverapamil 32 , valspodar 33 , tariquidar 34 , laniquidar 35 , and some of them have advanced into clinical trials 7 , 36 . Despite some P-gp inhibitors could significantly increase the efficacy of anticancer drugs in MDR cancer, none of the P-gp inhibitors have been approved for clinical use due to the drawbacks such as toxicity, interrupting drug–drug interactions, and so forth 37 . Therefore, the development of highly potent and specific P-gp inhibitors with good safety and favorable drug-like properties is still urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

Wang

Teng

Wang

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells

Cited by 8 publications

References 28 publications

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Magnetic Particles with Polymeric Shells Bearing Cholesterol Moieties Sensitize Breast Cancer Cells to Low Doses of Doxorubicin

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

Contact Info

Product

Resources

About